Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: A randomized, open-label, 12-week, parallel-group trial

Changsu Han, Chi Un Pae, Bun Hee Lee, Young-Hoon Ko, Prakash S. Masand, Ashwin A. Patkar, In Kwa Jung

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The present study was conducted to compare the effectiveness and tolerability of fluoxetine and sertraline in the treatment of undifferentiated somatoform disorder (USD), using the Patient Health Questionnaire (PHQ-15), which was specifically designed for assessing the severity of somatic symptoms. A randomized, 12-week, open-label trial of fluoxetine (10-60 mg/d) and sertraline (25-350 mg/d) in patients with USD was conducted. Six visits, at baseline and weeks 1, 2, 4, 8, and 12, were scheduled. Assessments for effectiveness and tolerability were conducted at each visit. The primary effectiveness measure was the mean change in PHQ-15 total score, from baseline to the end of treatment. Secondary effectiveness measures were the mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire (GHQ-12), from baseline to the end of treatment. A total of 45 subjects were enrolled; of them, 28 were randomly assigned to receive fluoxetine and 17 to receive sertraline. The total score on the PHQ-15 from baseline to the end of treatment significantly decreased in the fluoxetine (- 10.7, p < 0.0001) and sertraline (- 10.3, p < 0.0001) treatment groups, with no between-group difference (F = 0.0701, p = 0.7924). Overall, both treatments were well tolerated and no serious adverse event was reported. This study suggests that both agents may have a potential role in the treatment of USD. A double-blind, placebo-controlled trial and/or head-to-head comparison study with larger samples are required to draw more definite conclusions.

Original languageEnglish
Pages (from-to)437-444
Number of pages8
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume32
Issue number2
DOIs
Publication statusPublished - 2008 Feb 15

Fingerprint

Sertraline
Somatoform Disorders
Fluoxetine
Therapeutics
Health
Placebos
Depression
Equipment and Supplies

Keywords

  • Fluoxetine
  • Open-label
  • Patient Health Questionnaire
  • Sertraline
  • Undifferentiated somatoform disorder

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder : A randomized, open-label, 12-week, parallel-group trial. / Han, Changsu; Pae, Chi Un; Lee, Bun Hee; Ko, Young-Hoon; Masand, Prakash S.; Patkar, Ashwin A.; Jung, In Kwa.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, No. 2, 15.02.2008, p. 437-444.

Research output: Contribution to journalArticle

@article{b553992f09ae4d45be551ba486fd6bc5,
title = "Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: A randomized, open-label, 12-week, parallel-group trial",
abstract = "The present study was conducted to compare the effectiveness and tolerability of fluoxetine and sertraline in the treatment of undifferentiated somatoform disorder (USD), using the Patient Health Questionnaire (PHQ-15), which was specifically designed for assessing the severity of somatic symptoms. A randomized, 12-week, open-label trial of fluoxetine (10-60 mg/d) and sertraline (25-350 mg/d) in patients with USD was conducted. Six visits, at baseline and weeks 1, 2, 4, 8, and 12, were scheduled. Assessments for effectiveness and tolerability were conducted at each visit. The primary effectiveness measure was the mean change in PHQ-15 total score, from baseline to the end of treatment. Secondary effectiveness measures were the mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire (GHQ-12), from baseline to the end of treatment. A total of 45 subjects were enrolled; of them, 28 were randomly assigned to receive fluoxetine and 17 to receive sertraline. The total score on the PHQ-15 from baseline to the end of treatment significantly decreased in the fluoxetine (- 10.7, p < 0.0001) and sertraline (- 10.3, p < 0.0001) treatment groups, with no between-group difference (F = 0.0701, p = 0.7924). Overall, both treatments were well tolerated and no serious adverse event was reported. This study suggests that both agents may have a potential role in the treatment of USD. A double-blind, placebo-controlled trial and/or head-to-head comparison study with larger samples are required to draw more definite conclusions.",
keywords = "Fluoxetine, Open-label, Patient Health Questionnaire, Sertraline, Undifferentiated somatoform disorder",
author = "Changsu Han and Pae, {Chi Un} and Lee, {Bun Hee} and Young-Hoon Ko and Masand, {Prakash S.} and Patkar, {Ashwin A.} and Jung, {In Kwa}",
year = "2008",
month = "2",
day = "15",
doi = "10.1016/j.pnpbp.2007.09.014",
language = "English",
volume = "32",
pages = "437--444",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder

T2 - A randomized, open-label, 12-week, parallel-group trial

AU - Han, Changsu

AU - Pae, Chi Un

AU - Lee, Bun Hee

AU - Ko, Young-Hoon

AU - Masand, Prakash S.

AU - Patkar, Ashwin A.

AU - Jung, In Kwa

PY - 2008/2/15

Y1 - 2008/2/15

N2 - The present study was conducted to compare the effectiveness and tolerability of fluoxetine and sertraline in the treatment of undifferentiated somatoform disorder (USD), using the Patient Health Questionnaire (PHQ-15), which was specifically designed for assessing the severity of somatic symptoms. A randomized, 12-week, open-label trial of fluoxetine (10-60 mg/d) and sertraline (25-350 mg/d) in patients with USD was conducted. Six visits, at baseline and weeks 1, 2, 4, 8, and 12, were scheduled. Assessments for effectiveness and tolerability were conducted at each visit. The primary effectiveness measure was the mean change in PHQ-15 total score, from baseline to the end of treatment. Secondary effectiveness measures were the mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire (GHQ-12), from baseline to the end of treatment. A total of 45 subjects were enrolled; of them, 28 were randomly assigned to receive fluoxetine and 17 to receive sertraline. The total score on the PHQ-15 from baseline to the end of treatment significantly decreased in the fluoxetine (- 10.7, p < 0.0001) and sertraline (- 10.3, p < 0.0001) treatment groups, with no between-group difference (F = 0.0701, p = 0.7924). Overall, both treatments were well tolerated and no serious adverse event was reported. This study suggests that both agents may have a potential role in the treatment of USD. A double-blind, placebo-controlled trial and/or head-to-head comparison study with larger samples are required to draw more definite conclusions.

AB - The present study was conducted to compare the effectiveness and tolerability of fluoxetine and sertraline in the treatment of undifferentiated somatoform disorder (USD), using the Patient Health Questionnaire (PHQ-15), which was specifically designed for assessing the severity of somatic symptoms. A randomized, 12-week, open-label trial of fluoxetine (10-60 mg/d) and sertraline (25-350 mg/d) in patients with USD was conducted. Six visits, at baseline and weeks 1, 2, 4, 8, and 12, were scheduled. Assessments for effectiveness and tolerability were conducted at each visit. The primary effectiveness measure was the mean change in PHQ-15 total score, from baseline to the end of treatment. Secondary effectiveness measures were the mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire (GHQ-12), from baseline to the end of treatment. A total of 45 subjects were enrolled; of them, 28 were randomly assigned to receive fluoxetine and 17 to receive sertraline. The total score on the PHQ-15 from baseline to the end of treatment significantly decreased in the fluoxetine (- 10.7, p < 0.0001) and sertraline (- 10.3, p < 0.0001) treatment groups, with no between-group difference (F = 0.0701, p = 0.7924). Overall, both treatments were well tolerated and no serious adverse event was reported. This study suggests that both agents may have a potential role in the treatment of USD. A double-blind, placebo-controlled trial and/or head-to-head comparison study with larger samples are required to draw more definite conclusions.

KW - Fluoxetine

KW - Open-label

KW - Patient Health Questionnaire

KW - Sertraline

KW - Undifferentiated somatoform disorder

UR - http://www.scopus.com/inward/record.url?scp=38749088722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38749088722&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2007.09.014

DO - 10.1016/j.pnpbp.2007.09.014

M3 - Article

C2 - 17950970

AN - SCOPUS:38749088722

VL - 32

SP - 437

EP - 444

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 2

ER -